Tonix Pharmaceuticals Holding Corp. (TNXP)
NASDAQ: TNXP · Real-Time Price · USD
39.50
-0.95 (-2.35%)
Jun 4, 2025, 2:00 PM - Market open
TNXP Employees
Tonix Pharmaceuticals Holding had 81 employees as of December 31, 2024. The number of employees decreased by 22 or -21.36% compared to the previous year.
Employees
81
Change (1Y)
-22
Growth (1Y)
-21.36%
Revenue / Employee
$123,963
Profits / Employee
-$1,628,716
Market Cap
289.32M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
TNXP News
- 13 days ago - Tonix Pharmaceuticals Announces Presentation at the A.G.P. Annual Healthcare Company Showcase - GlobeNewsWire
- 14 days ago - Tonix Pharmaceuticals Announces First Patient Dosed in Phase 2 OASIS Study of TNX-102 SL for Reduction of Acute Stress Reaction - GlobeNewsWire
- 21 days ago - Tonix Pharmaceuticals Announces Appointment of Joseph Hand, Esq., as General Counsel and Executive Vice President of Operations - GlobeNewsWire
- 22 days ago - Tonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Highlights - GlobeNewsWire
- 5 weeks ago - Tonix Pharmaceuticals Presented Preclinical Data on Gastric Cancer Models at the American Association for Cancer Research (AACR) 2025 Annual Meeting - GlobeNewsWire
- 5 weeks ago - Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress Washington 2025 - GlobeNewsWire
- 7 weeks ago - Tonix Pharmaceuticals Announces Oral Presentation and Panel Participation at the World Vaccine Congress Washington 2025 - GlobeNewsWire
- 2 months ago - Tonix Pharmaceuticals and Makana Therapeutics Announce Collaboration Combining Tonix's Anti-CD40L Monoclonal Antibody (TNX-1500) with Makana's Genetically Engineered Organs in Preclinical and Clinical Xenotransplantation Studies - GlobeNewsWire